科研之友
微信
新浪微博
Facebook
分享链接
摘要
A series of co-engineered macrolide-mannitol particles were successfully prepared using azithromycin (AZ) as a model drug. The formulation was designed to target local inflammation and bacterial colonization, via the macrolide component, while the mannitol acted as mucolytic and taste-masking agent. The engineered particles were evaluated in terms of their physicochemical properties and aerosol performance when delivered via a novel high-payload dry powder Orbital (TM) inhaler device that operates via multiple inhalation manoeuvres. All formulations prepared were of suitable size for inhalation drug delivery and contained a mixture of amorphous AZ with crystalline mannitol. A co-spray dried formulation containing 200mg of 50: 50 w/w AZ: mannitol had 57.6%+/- 7.6% delivery efficiency with a fine particle fraction (<= 6.8 mm) of the emitted aerosol cloud being 80.4%+/- 1.1%, with minimal throat deposition (5.3 +/- 0.9%). Subsequently, it can be concluded that the use of this device in combination with the co-engineered macrolide-mannitol therapy may provide a means of treating bronchiectasis.
- 出版日期2015-5
- 单位河北医科大学
